12:00 AM
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Rilonacept: Completed Phase III enrollment

Regeneron disclosed in its 4Q10 earnings that it completed enrollment of about 1,200 patients taking urate-lowering drugs in the double-blind, international Phase III RE-SURGE trial...

Read the full 101 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >